Evogene
$ 0.60
2.40%
09 Jun - close price
- Market Cap 6,243,500 USD
- Current Price $ 0.60
- High / Low $ 0.62 / 0.57
- Stock P/E N/A
- Book Value -0.01
- EPS -1.70
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -1.72 %
- 52 Week High 2.03
- 52 Week Low 0.52
About
Evogene Ltd., is a computational biology company. The company is headquartered in Rehovot, Israel.
Analyst Target Price
$2.15
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-20 | 2026-03-05 | 2025-11-20 | 2025-08-28 | 2025-05-21 | 2025-03-06 | 2024-11-21 | 2024-08-22 | 2024-05-23 | 2024-03-07 | 2023-11-15 | 2023-08-17 |
| Reported EPS | -0.6095 | -0.6174 | -0.31 | -0.62 | -0.38 | 0.06 | -1.31 | -1.06 | -0.08 | -0.13 | -0.08 | -0.17 |
| Estimated EPS | -0.27 | -0.41 | -0.43 | -0.61 | -0.09 | -0.725 | -1.01 | -0.12 | -0.09 | -0.14 | -0.16 | -0.17 |
| Surprise | -0.3395 | -0.2074 | 0.12 | -0.01 | -0.29 | 0.785 | -0.3 | -0.94 | 0.01 | 0.01 | 0.08 | 0 |
| Surprise Percentage | -125.7407% | -50.5854% | 27.907% | -1.6393% | -322.2222% | 108.2759% | -29.703% | -783.3333% | 11.1111% | 7.1429% | 50% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EVGN
2026-06-09 11:10:13
Evogene (NASDAQ: EVGN) is set to present its AI-driven ChemPass AI platform and recent pharmaceutical division achievements at the BIO International Convention in San Diego from June 22-25, 2026. The company's management will highlight scientific and technological breakthroughs in AI-based small-molecule discovery and optimization, aiming to foster collaborative drug discovery opportunities. Despite recent positive clinical and AI-platform updates, the stock has experienced selling pressure following various company announcements, including Q1 2026 financial results and a Nasdaq minimum bid price notice.
2026-06-09 11:10:13
Evogene Ltd. announced it will present its pharma division's achievements at the BIO International Convention from June 22-25, 2026, in San Diego. Dr. Gabi Tarcic, Chief Development Officer, will deliver an oral presentation on the company's AI-driven small-molecule discovery technology, ChemPass AI™. Management will also be available for one-on-one meetings to discuss collaborative drug discovery opportunities.
2026-06-02 17:40:01
Evogene Ltd. announced the successful completion of a Phase 1 clinical study for BMC128, a cancer treatment that demonstrated safety and tolerability while showing encouraging signs of efficacy in patients with advanced solid tumors. Despite positive clinical results, Evogene faces financial challenges, with its stock declining significantly year-to-date and the company reporting a substantial net loss in Q1 2026. The company is, however, pursuing strategic initiatives, including a licensing agreement for BMC128 and focusing on its ChemPass AI platform, which has garnered investor interest.
2026-06-02 11:11:05
Evogene's subsidiary Biomica successfully completed a Phase 1 clinical study of BMC128, a live bacterial product, in combination with Nivolumab for advanced solid tumors. The study demonstrated a favorable safety profile and preliminary signs of anti-tumor activity, with some patients achieving stable disease and one partial response. These positive results support further clinical development of BMC128 (now designated LS-LBP-002) by Evogene's licensing partner, Lishan Biotech.
2026-06-02 11:00:22
Evogene (Nasdaq: EVGN) announced the successful completion of a Phase 1 clinical study of BMC128, a rationally designed live bacterial product, in combination with Nivolumab for patients with advanced solid tumors. The study met its primary safety endpoint with no dose-limiting toxicities and showed preliminary anti-tumor activity, including stable disease in five patients and one partial response. The positive results support continued development and commercialization by licensing partner Lishan Biotech.
2026-06-02 11:00:22
Evogene announced the successful completion of a Phase 1 clinical study of BMC128, a live bacterial product developed by its subsidiary Biomica, in combination with Nivolumab for advanced solid tumors. The study demonstrated a favorable safety profile and preliminary signals of anti-tumor activity, with some patients achieving stable disease and one a partial response. These positive results support further clinical development of BMC128 by licensing partner Lishan Biotech.
